SpringerLink
Log in

Use of Direct-Acting Oral Anticoagulants in Nonagenarians: A Call for More Data

  • Current Opinion
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

The prevalence and embolic risk of atrial fibrillation (AF) increase with age. Vitamin K antagonists (VKAs) or direct-acting oral anticoagulants (DOACs) reduce the risk of stroke or embolism. The aim of this review was to summarize the paucity of information regarding the safety and efficacy of DOACs in AF patients aged 90 years or older. The maximum age of included patients is not listed in any of the available DOAC investigating trials and registries, thus it is unclear if nonagenarians were included. Additionally, we could not find any subgroup analysis addressing this issue. There is an urgent need to collect more information on the safety and efficacy of oral anticoagulants in nonagenarians, especially regarding the role of DOACs, which are increasingly prescribed to this group of patients despite the lack of data. The best solution to this problem would be a prospective, randomized trial in this group of patients, however that would require a large investment of time, effort, and funds. In the meantime, we suggest subgroup analyses addressing the effects and safety of VKAs versus DOACs in nonagenarians, in case they have been included in previously completed or ongoing trials or registries. This could be feasible and would be desirable in view of the large amount of data already accumulated. Irrespective of age, anemia in patients receiving DOACs should be carefully investigated to rule out occult blood loss. With their known interaction profile and the possibility of monitoring these drugs, VKAs should be favored over DOACs in nonagenarians until more data are available regarding the safety of DOACs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386:154–62.

    Article  PubMed  Google Scholar 

  2. Dreischulte T, Barnett K, Madhok V, Guthrie B. Use of oral anticoagulants in atrial fibrillation is highly variable and only weakly associated with estimated stroke risk: cross-sectional population database study. Eur J Gen Pract. 2014;20:181–9.

    Article  PubMed  Google Scholar 

  3. Charlton B, Redberg R. The trouble with dabigatran. BMJ. 2014;349:g4681.

    Article  PubMed  Google Scholar 

  4. Deshpande A, Sampat P, Bhargavan R, Sharma M. Bleeding isolated jejunal varices without portal hypertension. ANZ J Surg. 2008;78:814–5.

    Article  PubMed  Google Scholar 

  5. Stöllberger C, Finsterer J. Concerns about the use of new oral anticoagulants for stroke prevention in elderly patients with atrial fibrillation. Drugs Aging. 2013;30:949–58.

    Article  PubMed  Google Scholar 

  6. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.

    Article  PubMed  Google Scholar 

  7. Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation. 2015;132:194–204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Sardar P, Chatterjee S, Chaudhari S, Lip GY. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc. 2014;62:857–64.

    Article  PubMed  Google Scholar 

  9. Lutz W, Sanderson W, Scherbov S. The coming acceleration of global population ageing. Nature. 2008;451:716–9.

    Article  CAS  PubMed  Google Scholar 

  10. Mandalenakis Z, Von Koch L, Eriksson H, Dellborg M, Caidahl K, Welin L, et al. The risk of atrial fibrillation in the general male population: a lifetime follow-up of 50-year-old men. Europace. 2015;17:1018–22.

    Article  PubMed  Google Scholar 

  11. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.

    Article  CAS  PubMed  Google Scholar 

  12. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.

    Article  CAS  PubMed  Google Scholar 

  13. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.

    Article  CAS  PubMed  Google Scholar 

  14. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.

    Article  CAS  PubMed  Google Scholar 

  15. Steinberg BA, Holmes DN, Ezekowitz MD, Fonarow GC, Kowey PR, Mahaffey KW, et al. Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF) registry. Am Heart J. 2013;165:622–9.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Beyer-Westendorf J, Förster K, Ebertz F, Gelbricht V, Schreier T, Göbelt M, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace. 2015;17:530–8.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, et al. GLORIA-AF Investigators. Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF Registry, Phase II. Am J Med. 2015;128(1306–13):e1.

    PubMed  Google Scholar 

  18. Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, et al. GARFIELD Registry Investigators. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013;8:e63479.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Hsu JC, Chan PS, Tang F, Maddox TM, Marcus GM. Differences in anticoagulant therapy prescription in patients with paroxysmal versus persistent atrial fibrillation. Am J Med. 2015;128:654.e1–654.e10.

  20. Lip GY, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L, et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J. 2014;35:3365–76.

    Article  PubMed  Google Scholar 

  21. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363–72.

    Article  CAS  PubMed  Google Scholar 

  22. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35:1864–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Xu Y, Holbrook AM, Simpson CS, Dowlatshahi D, Johnson AP. Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis. CMAJ Open. 2013;1:E115–9.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Olesen JB, Sørensen R, Hansen ML, Lamberts M, Weeke P, Mikkelsen AP, et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace. 2015;17:187–93.

    Article  PubMed  Google Scholar 

  25. Metcalfe S, Moodie P. National prescribing data for dabigatran. N Z Med J. 2012;125:97–105.

    PubMed  Google Scholar 

  26. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5:615–21.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012;366:864–6.

    Article  CAS  PubMed  Google Scholar 

  28. Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis. 2013;61:487–9.

    Article  CAS  PubMed  Google Scholar 

  29. Kernan L, Ito S, Shirazi F, et al. Fatal gastrointestinal hemorrhage after a single dose of dabigatran. Clin Toxicol (Phila). 2012;50:571–3.

    Article  CAS  PubMed  Google Scholar 

  30. Fontaine GV, Mathews KD, Woller SC, Stevens SM, Lloyd JF, Evans RS. Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. Clin Appl Thromb Hemost. 2014;20:665–72.

    Article  CAS  PubMed  Google Scholar 

  31. Lo JC, Gerona RR. A case of rivaroxaban associated intracranial hemorrhage. West J Emerg Med. 2014;15:375–7.

    Article  PubMed  PubMed Central  Google Scholar 

  32. King AE, Szarlej DK, Rincon F. Dabigatran-associated intracranial hemorrhage: literature review and institutional experience. Neurohospitalist. 2015;5:234–44.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Baumann D, Haap M, Tsaousidis C, Krämer B, Schreieck J, Jaschonek K, et al. Vaginal bleeding as symptom of a medical emergency: pitfalls of therapy with new oral anticoagulants—case 5/2014. Dtsch Med Wochenschr. 2014;139:1539.

    Article  PubMed  Google Scholar 

  34. Kramarow E, Chen LH, Hedegaard H, Warner M. Deaths from unintentional injury among adults aged 65 and over: United States, 2000-2013. NCHS Data Brief. 2015;199:199.

    PubMed  Google Scholar 

  35. Chang HY, Zhou M, Tang W, Alexander GC, Singh S. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ. 2015;350:h1585.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Goodman SG, Wojdyla DM, Piccini JP, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol. 2014;63:891–900.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015;350:h1857.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36(2):386–99.

    Article  CAS  PubMed  Google Scholar 

  39. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2009;37:1056–64.

    Article  CAS  PubMed  Google Scholar 

  40. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37:74–81.

    Article  CAS  PubMed  Google Scholar 

  41. Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012;40:2250–5.

    Article  CAS  PubMed  Google Scholar 

  42. Stöllberger C, Finsterer J. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Herz. 2015;40(Suppl 2):140–5.

    Article  PubMed  Google Scholar 

  43. Takahashi N, Inui N, Morita H, et al. Effect of thyroid hormone on the activity of CYP3A enzyme in humans. J Clin Pharmacol. 2010;50:88–93.

    Article  CAS  PubMed  Google Scholar 

  44. Böhm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol. 2015;65:2481–93.

    Article  PubMed  Google Scholar 

  45. Manzano-Fernández S, Andreu-Cayuelas JM, Marín F, Orenes-Piñero E, Gallego P, Valdés M, et al. Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation. Rev Esp Cardiol (Engl Ed). 2015;68:497–504.

    Article  PubMed  Google Scholar 

  46. Ruff CT, Giugliano RP, Braunwald E, Antman EM. New oral anticoagulants in patients with atrial fibrillation—authors’ reply. Lancet. 2014;384:25–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Krankenanstalt Rudolfstiftung, Steingasse 31/18, 1030, Vienna, Austria

    Claudia Stöllberger, Roman Brooks, Josef Finsterer & Thomas Pachofszky

Authors
  1. Claudia Stöllberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roman Brooks
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Josef Finsterer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas Pachofszky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claudia Stöllberger.

Ethics declarations

Funding

No external funding was used in the preparation of this manuscript.

Conflict of interest

Claudia Stöllberger, Roman Brooks, Josef Finsterer, Thomas Pachofszky declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stöllberger, C., Brooks, R., Finsterer, J. et al. Use of Direct-Acting Oral Anticoagulants in Nonagenarians: A Call for More Data. Drugs Aging 33, 315–320 (2016). https://doi.org/10.1007/s40266-016-0363-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-016-0363-4

Keywords

Search

Navigation